Abstract:With the COVID-19 pandemic behind us, the U.S. Food and Drug Administration (FDA) has approved 55 new drugs in 2023, a figure consistent with the number authorized in the last five years (53 per year on average). Thus, 2023 marks the second-best yearly FDA harvest after 2018 (59 approvals) in all the series. Monoclonal antibodies (mAbs) continue to be the class of drugs with the most approvals, with an exceptional 12, a number that makes it the most outstanding year for this class. As in 2022, five proteins/enzymes have been approved in 2023. However, no antibody–drug conjugates (ADCs) have been released onto the market. With respect to TIDES (peptides and oligonucleotides), 2023 has proved a spectacular year, with a total of nine approvals, corresponding to five peptides and four oligonucleotides. Natural products continue to be the best source of inspiration for drug development, with 10 new products on the market. Three drugs in this year's harvest are pegylated, which may indicate the return of pegylation as a method to increase the half-lives of drugs after the withdrawal of peginesatide from the market in 2013. Following the trends in recent years, two bispecific drugs have been authorized in 2023. As in the preceding years, fluorine and/or N-aromatic heterocycles are present in most of the drugs. Herein, the 55 new drugs approved by the FDA in 2023 are analyzed exclusively on the basis of their chemical structure. They are classified as the following: biologics (antibodies, proteins/enzymes); TIDES (peptide and oligonucleotides); combined drugs; pegylated drugs; natural products; nitrogen aromatic heterocycles; fluorine-containing molecules; and other small molecules.

New drug approvals for 2020: Synthesis and clinical applications

New drug approvals for 2021: Synthesis and clinical applications

New drug approvals for 2019: Synthesis and clinical applications

A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect

Synthesis and clinical application of new drugs approved by FDA in 2023

A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects

Synthetic Approaches to the New Drugs Approved During 2022

The mechanism of action and chemical synthesis of FDA newly approved drug molecules

The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023

Small molecule anticancer drugs approved during 2021-2022: Synthesis and clinical applications

A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions

2020 FDA drug approvals

Status quo of domestically approved small molecule drugs against novel coronavirus and their application

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules

An update of new small-molecule anticancer drugs approved from 2015 to 2020

Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025)

New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use

Fluorine-containing drugs approved by the FDA in 2021

A comprehensive review of discovery and development of drugs discovered from 2020-2022